Abstract
Background: SIRT2 belongs to a class Ill of Histone Deacetylase (HDAC) and has crucial roles in neurodegeneration and malignancy.
Objective: The objective of this study is to discover structurally novel natural-product-derived SIRT2 inhibitors.
Methods: Structure-based pharmacophore modeling integrated with validated QSAR. analysis was implemented to discover structurally novel SIRT2 inhibitors from the natural products database. The targeted QSAR model combined molecular descriptors with structure-based pharmacophore capable of explaining bioactivity variation of structurally diverse SIRT2 inhibitors. Manually built pharmacophore model, validated with receiver operating characteristic curve, and selected using the statistically optimum QSAR equation, was applied as a 3D-search query to mine AnalytiCon Discovery database of natural products.
Results: Experimental in vitro testing of highest-ranked hits identified asperphenamate and salvianolic acid B as active SIRT2 inhibitors with IC50 values in low micromolar range.
Conclusion: New chemical scaffolds of SIRT2 inhibitors have been identified that could serve as a starting point for lead-structure optimization.